Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.535 -0.095 (-2.05%)
Streaming Delayed Price Updated: 9:47 AM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,843,931
Open 4.600
Bid (Size) 4.530 (45)
Ask (Size) 4.540 (116)
Prev. Close 4.630
Today's Range 4.520 - 4.620
52wk Range 3.790 - 12.36
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts
Nvidia's six-stock portfolio of publicly traded AI stocks was worth $4.3 billion at the end of the second quarter, and the company also owns stakes in many privately held AI start-ups. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Regulatory Compliance
3 AI Stocks Disrupting Trillion-Dollar Industries
These three companies are using artificial intelligence (AI) to transform defense, pharmaceuticals, and banking. 
Via The Motley Fool
Topics Artificial Intelligence Economy

Performance

YTD
-37.1%
-37.1%
1 Month
-21.8%
-21.8%
3 Month
-7.6%
-7.6%
6 Month
-31.1%
-31.1%
1 Year
-25.3%
-25.3%

More News

Read More
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Topics Artificial Intelligence
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For August 5, 2025
Via Benzinga
Recursion Pharmaceuticals Earnings Preview
Via Benzinga
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
From Recursion Pharmaceuticals
Via GlobeNewswire
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
Via The Motley Fool
Topics Artificial Intelligence
Why Recursion Pharmaceuticals Stock Caught a Cold This Week
Via The Motley Fool
Topics Regulatory Compliance
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
Via FinancialNewsMedia
Topics Artificial Intelligence
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Via The Motley Fool
Topics Artificial Intelligence
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
Via The Motley Fool
Recursion (RXRX) Q2 Revenue Jumps 33%
Via The Motley Fool
Topics Artificial Intelligence
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates
Via Benzinga
Recursion Pharmaceuticals-A (NASDAQ:RXRX) Reports Mixed Q2 2025 Earnings: Revenue Beat but EPS Miss
Via Chartmill
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
The Dawn of Hyper-Personalization: How Generative AI is Reshaping Our Digital World
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
2 Beaten-Down Stocks With Incredible Upside Potential
Via The Motley Fool
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
Via The Motley Fool
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Topics Artificial Intelligence Retirement
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Via Benzinga
Topics Artificial Intelligence ETFs
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
Via Benzinga
3 AI Stocks Partnered With Nvidia With Massive Growth Opportunities
Via The Motley Fool
Topics Artificial Intelligence

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 4.535
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 09/04/25 09:47 AM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 763.81M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 764M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.